see Glivec

Imatinib is a drug used to treat certain types of cancer. It is currently marketed by Novartis as Gleevec® (USA) or Glivec® (Europe/Australia) as its mesylate salt, imatinib mesilate (INN). It is occasionally still referred to as CGP57148B or STI571 (especially in older publications).

a selective inhibitor of BCR-ABL tyrosine kinase which has recently been approved for the treatment of interferon-refractory or intolerant chronic myelogenous leukemia (CML)